LENZ — LENZ Therapeutics, Inc.

LENZ Therapeutics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $1.9 million, including $1.7 million from product sales.
• Prescriptions: Approximately 25,000 paid and filled prescriptions, a 19% increase from Q4 2025, totaling about 46,000 since launch.
• Operating Expenses: Total SG&A expenses rose to $45 million, a 13% increase quarter-over-quarter, primarily due to direct-to-consumer (DTC) launch investments.
• Net Loss: $41.5 million, translating to a net loss per share of $1.32.
• Cash Position: Ended Q1 with approximately $258.4 million in cash and equivalents, with a consistent cash burn of $34 million.

2. Strategic Updates and Business Highlights

• Product Performance: VIZZ is showing strong real-world efficacy, with over 10,000 unique prescribers and encouraging refill behaviors, particularly with 3-month prescriptions comprising over 66% of e-pharmacy volume.
• Market Positioning: The company is focusing on building a new category for presbyopia treatment, with a strong emphasis on integrating VIZZ into standard eye exams and enhancing physician-patient conversations.
• Direct Sales Initiative: LENZ is enabling eye care professionals (ECPs) to sell VIZZ directly in their practices, aiming to improve patient access and reduce prescription abandonment.
• Global Expansion: Ongoing efforts to expand internationally, with recent submissions in Europe and the UK, alongside interest from potential partners in various regions.

3. Forward Guidance and Outlook

• Management anticipates that the actions taken to improve adoption will lead to meaningful growth in prescriptions over the coming quarters.
• The company plans to provide more detailed refill dynamics and patient behavior insights in the second half of 2026.
• Continued focus on executing marketing strategies and refining the patient experience to drive adoption.

4. Bad News, Challenges, or Points of Concern

• Slow Adoption Rates: New patient adoption is growing but not at the desired pace, with the need for physicians to integrate VIZZ more proactively into patient discussions.
• Competitive Pressures: New entrants like Yuvezzi and Qlosi have launched, raising concerns about market competition and the effectiveness of LENZ's sampling strategy.
• Operational Challenges: The company faced nonrecurring costs related to inventory issues and packaging, which impacted cost of sales.
• High SG&A Expenses: Continued high operating expenses, particularly in sales and marketing, may pressure profitability in the short term.

5. Notable Q&A Insights

• ECP Engagement: There is a need for ECPs to incorporate VIZZ into their standard exam flow more effectively. Strategies are being implemented to facilitate this.
• Refill Dynamics: The company plans to share more specific refill data later in the year, as they want to observe patient behavior over time.
• Safety Profile: VIZZ has shown a favorable safety profile with minimal adverse events reported, reinforcing confidence in the product's market position.
• Direct Sales Model: The direct sales initiative is driven by ECP demand rather than prescription abandonment concerns, aiming to enhance convenience for patients.

Overall, LENZ Therapeutics is navigating the early stages of its product launch with a focus on refining its strategies to drive adoption and manage operational challenges while maintaining a strong cash position for future growth.